| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
*
Veterans Affairs Medical Center, Memphis, TN 38104; Departments of
Medicine and
Pathology, University of Tennessee, Memphis, TN 38163; and
Department of Molecular Immunology, Merck Research Laboratories, Rahway, NJ 07065
Rheumatoid arthritis is an autoimmune disease in which susceptibility is strongly associated with the expression of specific HLA-DR haplotypes, including DR1 (DRB1*0101) and DR4 (DRB1*0401). As transgenes, both of these class II molecules mediate susceptibility to an autoimmune arthritis induced by immunization with human type II collagen (hCII). The dominant T cell response of both the DR1 and DR4 transgenic mice to hCII is focused on the same determinant core, CII(263–270). Peptide binding studies revealed that the affinity of DR1 and DR4 for CII(263–270) was at least 10 times less than that of the model Ag HA(307–319), and that the affinity of DR4 for the CII peptide is 3-fold less than that of DR1. As predicted based on the crystal structures, the majority of the CII-peptide binding affinity for DR1 and DR4 is controlled by the Phe263; however, unexpectedly the adjacent Lys264 also contributed significantly to the binding affinity of the peptide. Only these two CII amino acids were found to provide binding anchors. Amino acid substitutions at the remaining positions had either no effect or significantly increased the affinity of the hCII peptide. Affinity-enhancing substitutions frequently involved replacement of a negative charge, or Gly or Pro, hallmark amino acids of CII structure. These data indicate that DR1 and DR4 bind this CII peptide in a nearly identical manner and that the primary structure of CII may dictate a different binding motif for DR1 and DR4 than has been described for other peptides that bind to these alleles.
This article has been cited by other articles:
|
|
 |
|
  B. Jahn-Schmid, P. Sirven, V. Leb, W. F. Pickl, G. F. Fischer, G. Gadermaier, M. Egger, C. Ebner, F. Ferreira, B. Maillere, et al. Characterization of HLA Class II/Peptide-TCR Interactions of the Immunodominant T Cell Epitope in Art v 1, the Major Mugwort Pollen Allergen J. Immunol., September 1, 2008; 181(5): 3636 - 3642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Taneja, M. Behrens, E. Basal, J. Sparks, M. M. Griffiths, H. Luthra, and C. S. David Delineating the Role of the HLA-DR4 "Shared Epitope" in Susceptibility versus Resistance to Develop Arthritis J. Immunol., August 15, 2008; 181(4): 2869 - 2877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Huan, L. J. Kaler, J. L. Mooney, S. Subramanian, C. Hopke, A. A. Vandenbark, E. F. Rosloniec, G. G. Burrows, and H. Offner MHC Class II Derived Recombinant T Cell Receptor Ligands Protect DBA/1LacJ Mice from Collagen-Induced Arthritis J. Immunol., January 15, 2008; 180(2): 1249 - 1257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Richards, F. A. Chaves, F. R. Krafcik, D. J. Topham, C. A. Lazarski, and A. J. Sant Direct Ex Vivo Analyses of HLA-DR1 Transgenic Mice Reveal an Exceptionally Broad Pattern of Immunodominance in the Primary HLA-DR1-Restricted CD4 T-Cell Response to Influenza Virus Hemagglutinin J. Virol., July 15, 2007; 81(14): 7608 - 7619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. von Delwig, D. M Altmann, F. G Charlton, N. McKie, J. D Isaacs, R. Holmdahl, and J. H Robinson T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice Ann Rheum Dis, May 1, 2007; 66(5): 599 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-Q. Yao, R. Li, and Z.-G. Li A triple altered collagen II peptide with consecutive substitutions of TCR contacting residues inhibits collagen-induced arthritis Ann Rheum Dis, March 1, 2007; 66(3): 423 - 424. [Full Text] [PDF]
|
|
|
|
|
|
E. F. Rosloniec, R. A. Ivey III, K. B. Whittington, A. H. Kang, and H.-W. Park Crystallographic Structure of a Rheumatoid Arthritis MHC Susceptibility Allele, HLA-DR1 (DRB1*0101), Complexed with the Immunodominant Determinant of Human Type II Collagen J. Immunol., September 15, 2006; 177(6): 3884 - 3892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Dzhambazov, K. S. Nandakumar, J. Kihlberg, L. Fugger, R. Holmdahl, and M. Vestberg Therapeutic Vaccination of Active Arthritis with a Glycosylated Collagen Type II Peptide in Complex with MHC Class II Molecules J. Immunol., February 1, 2006; 176(3): 1525 - 1533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Xia, L Ru, and L Zhanguo Altered influenza virus haemagglutinin peptides inhibit T cell responses to type II collagen in rheumatoid arthritis Ann Rheum Dis, December 1, 2005; 64(12): 1790 - 1791. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Cremer, X. J. Ye, L. K. Myers, D. D. Brand, E. F. Rosloniec, and A. H. Kang T Cell Immunity to Type II Collagen in the Biobreeding Rat: The Identification and Characterization of RT1u-Restricted T Cell Epitopes on {alpha}1(II) J. Immunol., August 1, 2004; 173(3): 1795 - 1801. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
